Yes, some cannabis companies can obtain federal trademark protection, but federal registration is not available automatically to every marijuana business. Eligibility depends on the particular goods or services, whether the underlying commercial activity complies with federal law, and, for certain medical marijuana businesses, whether applicable state licensing and federal DEA requirements are satisfied.
A major federal change took effect on April 28, 2026. Certain FDA-approved marijuana drug products and marijuana products subject to qualifying state medical-marijuana licenses were placed in Schedule III of the Controlled Substances Act.
That change created a potentially significant new pathway for some medical marijuana businesses seeking federal trademark protection.
It did not broadly legalize marijuana under federal law, and it did not make every dispensary, cultivator, manufacturer, recreational cannabis company, or marijuana brand automatically eligible for USPTO registration.
For cannabis businesses, the first question is therefore not simply whether the brand name is available. The business must determine whether the specific goods or services identified in the trademark application can support lawful federal trademark use.
Key Takeaways for Cannabis Trademark Applicants
Federal trademark registration requires lawful use in commerce or a bona fide intention to make lawful use. The April 28, 2026 federal rule created Schedule III treatment for FDA-approved marijuana drug products and marijuana covered by qualifying state medical-marijuana licenses. Adult-use marijuana remains outside that limited framework unless and until broader federal rescheduling becomes final. State licensing alone does not eliminate all federal requirements. Hemp-derived products follow a separate analysis, and ancillary cannabis businesses may have federal trademark options for independently lawful goods or services.
Can a Cannabis Company Get a Federal Trademark?
Sometimes.
A cannabis company may qualify for federal trademark registration when the trademark is used, or genuinely intended to be used, with goods or services that comply with applicable federal law.
This requirement comes from the basic federal trademark rule that use in commerce must be lawful.
TMEP §907 explains that when a product is regulated under an Act of Congress, the USPTO may inquire into compliance with federal law to determine whether the commerce identified in the application is lawful.
The USPTO generally presumes commercial activity is lawful. However, when the application record shows that the goods or services violate federal law, the examining attorney can issue an inquiry or refusal.
For cannabis companies, the relevant evidence may include the identification of goods and services, specimen, product packaging, website, advertisements, licenses, ingredients, THC information, and the applicant’s description of its business.
Why Has Federal Trademark Protection Historically Been Difficult for Marijuana Businesses?
Federal marijuana law historically created a fundamental lawful-use problem.
Even when a business operated legally under a state marijuana program, marijuana remained a Schedule I controlled substance under the federal Controlled Substances Act.
Federal trademark law does not treat state legality as a substitute for federal legality.
The Trademark Trial and Appeal Board has repeatedly applied this principle in cases involving cannabis-related goods and services. Earlier decisions such as In re Brown and In re PharmaCann LLC confirmed that activities permitted under state marijuana laws could still fail the federal lawful-use requirement.
This is why cannabis companies historically had difficulty registering trademarks for marijuana itself, dispensary services involving marijuana, and other activities directly prohibited by the Controlled Substances Act.
The federal landscape changed in April 2026, but only for specified categories.
What Changed for Marijuana on April 28, 2026?
On April 28, 2026, a Department of Justice and Drug Enforcement Administration final rule took effect addressing specified marijuana products and medical-marijuana activity.
The rule placed FDA-approved drug products containing marijuana in Schedule III.
It also applies Schedule III treatment to marijuana and marijuana products subject to qualifying state-issued licenses to manufacture, distribute, or dispense marijuana for medical purposes.
The final rule established an expedited federal registration process for entities holding qualifying state medical-marijuana licenses.
This is an important development for trademark law because one of the principal historical obstacles to federal registration was the Schedule I status of the underlying marijuana activity.
For qualifying medical-marijuana businesses operating within the new framework, that categorical obstacle may no longer apply in the same way.
That does not mean USPTO registration becomes automatic.
Did Marijuana Become Schedule III Nationwide in 2026?
Not generally.
The April 2026 final rule should not be confused with the separate federal proceeding considering whether marijuana as a whole should be transferred from Schedule I to Schedule III.
The April final rule covers specified FDA-approved marijuana products and marijuana subject to qualifying state medical-marijuana licenses.
A separate rulemaking proceeding continues to consider broader rescheduling.
DEA conducted formal hearings on the broader proposal between June 29 and July 15, 2026.
As of September 1, 2026, DEA continues to characterize that broader action as a proposed rescheduling proceeding rather than a final rule applicable to marijuana generally.
This distinction is critical for cannabis trademark applicants.
A proposed rule, administrative hearing, political announcement, or recommendation does not create the same trademark consequences as an effective final federal rule.
Can a Medical Marijuana Company Obtain a Federal Trademark in 2026?
Potentially, yes.
The April 2026 rule creates a significantly more viable federal pathway for businesses whose marijuana activity falls within a qualifying state medical-marijuana license and the applicable federal framework.
A company should not assume, however, that possession of a state medical-marijuana license automatically establishes federal trademark eligibility.
Entities that manufacture, distribute, or dispense marijuana under the new framework may also need the appropriate DEA registration.
The final rule establishes federal registration procedures for state-licensed medical-marijuana entities and imposes requirements relating to the handling of covered marijuana.
A trademark applicant relying on this framework should therefore determine whether its particular business activity falls within the final rule and whether the company has complied with federal registration requirements applicable to that activity.
Is a State Medical Marijuana License Enough for a USPTO Application?
Not necessarily.
A qualifying state medical-marijuana license is now much more significant under federal law than it was before April 28, 2026.
But the federal rule does not simply declare every licensed medical-marijuana business free from federal regulation.
The Controlled Substances Act continues to regulate Schedule III substances.
Businesses handling covered marijuana may be subject to DEA registration, recordkeeping, prescribing, dispensing, inventory, security, distribution, and other federal requirements, although the April 2026 framework includes specialized provisions for state medical-marijuana licensees.
For trademark purposes, the practical question is whether the applicant’s actual activity constitutes lawful federal commerce.
A company should therefore be prepared to establish the nature of its state authorization and, when applicable, its DEA registration and compliance with the federal framework.
Can a Medical Marijuana Dispensary Obtain a Federal Trademark?
Potentially, under the new 2026 framework.
Before April 2026, dispensary services involving marijuana generally faced a serious federal lawful-use obstacle even when the dispensary was licensed under state law.
The new federal rule provides a registration pathway for dispensers operating under qualifying state medical-marijuana licenses.
DEA has also established a registration process specifically relevant to medical-marijuana dispensaries.
A qualifying medical-marijuana dispensary may therefore have a substantially stronger basis for pursuing federal trademark protection than a dispensary operating only in an adult-use recreational market.
The applicant should nevertheless confirm that its actual activities fall within the medical-marijuana framework and satisfy applicable federal registration requirements.
The identification of services should accurately reflect those activities.
Can a Recreational Marijuana Dispensary Get a Federal Trademark?
Adult-use marijuana businesses remain in a substantially more difficult position.
The April 2026 rule was not a general federal legalization of recreational marijuana.
Marijuana outside the categories covered by the final rule remains subject to the Controlled Substances Act framework applicable to Schedule I marijuana unless another federal rule applies.
Accordingly, a dispensary operating solely under a state recreational or adult-use marijuana license should not assume that the 2026 medical-marijuana changes make its dispensary services federally lawful.
This distinction should be addressed before filing a federal application for services that directly involve recreational marijuana.
State trademark protection and federal protection for separately lawful portions of the business may still be worth considering.
What Is Happening With the Broader Federal Marijuana Rescheduling Proposal?
The federal government continues to consider whether marijuana generally should be transferred from Schedule I to Schedule III.
The broader proposal originated in a May 2024 notice of proposed rulemaking.
After procedural developments affecting the original hearing process, the Department of Justice initiated a new hearing process in April 2026.
DEA held formal proceedings beginning June 29, 2026 and scheduled them to conclude by July 15, 2026.
As of September 1, 2026, DEA’s current regulatory materials continue to treat this as a proposed rescheduling action.
Cannabis companies should therefore distinguish between two developments.
The first is the April 28, 2026 final rule that already applies to specified FDA-approved and state-licensed medical marijuana.
The second is the broader proposal concerning marijuana generally, which has not yet become a final across-the-board Schedule III rule.
For trademark planning, only law currently in effect should be treated as an established basis for federal commercial activity.
Can a Company Trademark an FDA-Approved Marijuana Drug?
Potentially, yes.
The April 2026 final rule expressly places qualifying FDA-approved drug products containing marijuana in Schedule III.
A company involved with such a product may therefore have a pathway toward lawful federal trademark use that differs from an ordinary marijuana product.
The trademark analysis does not end with FDA approval.
Manufacturers, distributors, dispensers, researchers, importers, exporters, and other entities handling controlled substances may have separate DEA requirements.
Trademark ownership must also be considered independently.
The company that manufactures or distributes a drug product is not automatically the owner of the associated trademark.
The applicant should be the legal entity that owns the mark or, for an intent-to-use application, possesses the required bona fide intention to use it.
Does Schedule III Status Automatically Mean the USPTO Will Register the Mark?
No.
Resolving a Controlled Substances Act problem eliminates only one possible trademark obstacle.
The USPTO will still examine the application under ordinary federal trademark rules.
A proposed cannabis trademark can still be refused because it is confusingly similar to an earlier mark, merely descriptive, generic, geographically descriptive, deceptively misdescriptive, or otherwise unregistrable.
The application may also encounter ownership, identification, filing-basis, or specimen problems.
In other words, federal legality does not equal trademark availability.
A qualifying medical-marijuana business should still conduct a comprehensive trademark search before investing substantially in a new brand.
Can a Cannabis Company Register a Trademark for Hemp Products?
Potentially, but hemp and marijuana should be analyzed separately.
Qualifying hemp was removed from the federal Controlled Substances Act definition of marijuana under the 2018 Farm Bill framework.
That opened a federal trademark pathway for many hemp-related products.
The fact that a product is hemp-derived does not automatically establish federal legality, particularly when CBD, food, dietary supplements, drugs, cosmetics, or therapeutic claims are involved.
Other federal statutes, including the Federal Food, Drug, and Cosmetic Act, can still apply.
The federal definition of hemp is also scheduled to change on November 12, 2026.
Cannabis companies selling both marijuana and hemp-derived products should therefore avoid combining the two categories indiscriminately within a trademark application.
Each product should be evaluated under the federal law that applies to it.
Can a Cannabis Company Register Its Brand for CBD Products?
Sometimes.
CBD trademark eligibility depends on the specific product.
A hemp-derived CBD topical cosmetic may present a different federal analysis from CBD gummies, dietary supplements, beverages, or therapeutic products.
The FDA continues to take the position that CBD cannot presently be marketed as a conventional dietary supplement under the existing federal framework and that introducing food with added CBD into interstate commerce is prohibited, subject to limited statutory exceptions.
Accordingly, a cannabis company cannot necessarily obtain federal trademark protection for a CBD product merely by describing it as hemp-derived.
The nature of the product and all applicable federal laws must be reviewed.
Can Ancillary Cannabis Businesses Obtain Federal Trademarks?
Often, ancillary businesses have a more straightforward federal trademark path because their goods or services may be independently lawful.
A company can participate in the cannabis industry without growing, manufacturing, distributing, or selling marijuana.
Businesses may provide software, accounting, consulting, publications, packaging technology, agricultural equipment, lighting systems, general business services, compliance tools, or other goods and services to cannabis companies.
Federal trademark registration may be available when the applicant’s own activity is lawful.
The precise identification remains important.
A software company providing inventory-management technology to dispensaries, for example, should identify its software or technology services accurately rather than broadly describing itself as providing marijuana-distribution services if it does not perform those activities.
The USPTO will evaluate what the applicant actually provides.
Can Cannabis Software Companies Obtain Federal Trademark Protection?
Potentially.
A software company serving cannabis businesses is not necessarily engaged in the manufacture or sale of marijuana.
For example, software used for inventory management, accounting, scheduling, compliance, customer management, or business analytics may constitute independently lawful technology services.
The fact that customers operate within the cannabis industry does not automatically make the software itself a controlled substance.
However, the exact nature of the service still matters.
An identification should not suggest that the software company itself performs federally prohibited cannabis activities when it merely supplies technology to other businesses.
A cannabis technology company should therefore draft the identification around the actual software or SaaS functionality it provides.
Can a Cannabis Company Trademark Clothing or Merchandise?
Yes, potentially, if the company operates a genuine clothing or merchandise business and uses the mark as a trademark for those goods.
A cannabis company may sell lawful shirts, hats, bags, or other merchandise under its brand.
A federal registration covering clothing protects trademark rights associated with the clothing identified in the registration.
It does not automatically protect marijuana flower, edibles, concentrates, dispensary services, or other cannabis products.
This distinction is particularly important for businesses trying to use merchandise as a substitute for registration of their principal cannabis activity.
Trademark protection is tied to the goods and services covered by the registration.
Can a Cannabis Company Sell a Few Shirts Just to Get a Federal Trademark?
Token merchandise is not a reliable shortcut to federal trademark protection for a marijuana brand.
Federal trademark use requires use in the ordinary course of trade rather than activity manufactured solely to reserve rights.
A company that genuinely operates a clothing line may have legitimate trademark use for clothing.
A handful of artificial transactions created only to produce a trademark specimen may raise questions about whether genuine commercial use exists.
The trademark must also function as a source identifier.
If the cannabis brand appears only as a large decorative slogan across the front of a shirt, the USPTO may additionally question whether the use is merely ornamental rather than trademark use for clothing.
Most importantly, even a valid clothing registration does not create a federal registration for marijuana.
How Should a Cannabis Company Describe Its Goods or Services?
Cannabis trademark applications require unusually careful identification drafting.
Terms such as “cannabis products,” “marijuana products,” or “cannabis retail services” may be too broad to reveal whether the activity falls within a federally lawful category.
A stronger identification should describe what the business actually offers.
Depending on the circumstances, the application may need to distinguish among qualifying state-licensed medical marijuana, FDA-approved drug products, hemp-derived goods, software, clothing, educational services, or another independently lawful category.
An applicant relying on medical-marijuana activity should consider whether the identification accurately reflects the limitations of the applicable licensing and federal framework.
Vague wording should not be used to conceal the nature of the business.
The USPTO can request additional information when the record raises legitimate questions about lawful use.
Can the USPTO Ask for Cannabis Licenses or Regulatory Information?
Yes.
Under 37 C.F.R. §2.69 and TMEP §907, the USPTO may make an appropriate inquiry regarding compliance with federal law when the sale or transportation of the relevant product is federally regulated.
For cannabis-related applications, an examining attorney may therefore request information necessary to understand the applicant’s goods or services and determine whether the claimed commerce is lawful.
Depending on the application, relevant information could concern ingredients, cannabinoid content, state licensing, DEA registration, FDA approval, intended use, or the nature of the applicant’s services.
Cannabis businesses should not assume that a carefully worded identification will prevent the USPTO from examining evidence that reveals what the business actually does.
Can a Cannabis Company File an Intent-to-Use Trademark Application?
Potentially.
Section 1(b) of the Trademark Act allows an applicant to file before beginning commercial use if it possesses a bona fide intention to use the mark in commerce.
An intent-to-use application does not eliminate the requirement that the intended commercial activity be lawful.
TMEP §907 explains that when identified goods or services cannot lawfully be offered, the applicant may be unable to possess the required bona fide intention to make lawful use of the mark.
For a medical-marijuana business relying on the 2026 framework, the company should have a credible path toward satisfying state licensing, DEA registration, and other applicable federal requirements.
An adult-use cannabis company should not rely solely on the possibility that the broader marijuana-rescheduling proposal might become final in the future.
Can a Cannabis Trademark Specimen Cause a Lawful-Use Refusal?
Yes.
A specimen provides evidence of how the trademark is actually used in commerce.
For goods, qualifying specimens can include product labels, containers, packaging, tags, and appropriate point-of-sale displays.
For services, a specimen might include a website or advertisement that directly associates the trademark with the claimed services.
Cannabis companies should review specimens for more than technical trademark requirements.
A specimen can reveal that the applicant’s actual activities differ from the identification.
For example, an application might describe retail services involving qualifying medical marijuana while the submitted webpage prominently advertises unrestricted recreational cannabis sales.
Product packaging might reveal THC content, therapeutic claims, or another fact relevant to federal law.
The application, identification, specimen, website, licenses, and actual business operations should therefore be consistent.
Can a Cannabis Trademark Be Refused for Likelihood of Confusion?
Yes.
Cannabis businesses remain subject to Section 2(d) of the Trademark Act.
The USPTO may refuse registration when a proposed mark is sufficiently similar to an earlier registered trademark and the respective goods or services are sufficiently related that consumers are likely to believe they originate from the same source.
The marks do not have to be identical.
Cannabis companies frequently operate in adjacent markets involving wellness, cosmetics, pharmaceuticals, hemp, retail services, food, technology, agriculture, and consumer products.
A proposed cannabis brand should therefore be searched beyond exact matches and beyond businesses selling the identical product.
Can a Cannabis Trademark Be Refused as Descriptive?
Yes.
Cannabis branding frequently uses repeated vocabulary involving concepts such as green, herb, leaf, high, elevated, wellness, relief, natural, organic, medical, and cannabis itself.
A mark may be merely descriptive if it immediately communicates an ingredient, quality, characteristic, purpose, function, or feature of the goods or services.
Highly descriptive naming can make registration more difficult and may also result in narrower enforceable trademark rights.
Selecting a distinctive brand before launch can therefore improve both registrability and long-term brand protection.
Can a Recreational Cannabis Company Protect Its Brand Without a Federal Registration?
Potentially, through other forms of protection.
When federal trademark registration is unavailable for the company’s principal marijuana goods or services, state trademark registration may be available under the laws of a state where the activity is lawful.
State-law trademark and unfair-competition rights may also arise depending on the jurisdiction and actual commercial use.
Cannabis businesses can additionally consider federal registrations for independently lawful goods or services when legitimate commercial use exists.
Other brand-protection tools may include domain-name protection, contractual ownership provisions, licensing agreements, marketplace controls, copyright protection for qualifying creative works, and monitoring for confusingly similar brands.
These mechanisms do not necessarily provide the same nationwide benefits as a federal trademark registration covering the core goods or services.
Who Should Own a Cannabis Trademark?
The correct trademark owner should be determined before the application is filed.
Cannabis companies often use complicated entity structures because separate companies may hold intellectual-property assets, cultivation licenses, manufacturing licenses, dispensary licenses, real estate, distribution operations, or management functions.
Trademark ownership does not necessarily have to sit with the company that holds every operational license, but the structure must reflect genuine ownership and control of the mark.
When one entity owns the trademark and licenses it to operating companies, appropriate quality control is important.
The applicant named in the federal trademark application must also satisfy the ownership requirements applicable to the filing basis.
A use-based application filed by an entity that did not own the trademark on the application filing date may present a serious defect.
Can One Cannabis Trademark Cover Medical and Recreational Marijuana?
Not automatically.
A trademark registration covers the specific goods or services identified in the registration.
If a company operates both a qualifying medical-marijuana business and a recreational marijuana business under the same brand, federal registrability of one category does not necessarily establish registrability of the other.
The lawful medical activity may potentially support federal registration under the 2026 framework.
The adult-use activity may remain outside that federal pathway.
The company should therefore avoid assuming that one registration will automatically federalize every use of the brand across its cannabis operations.
What Should a Cannabis Company Review Before Filing With the USPTO?
The business should begin by identifying the precise goods and services offered under the proposed mark.
It should then determine whether each category is lawful under the federal framework currently in effect.
For medical-marijuana businesses, that review may involve state licensing and DEA registration under the April 2026 rule.
For hemp businesses, it may require analysis under the federal hemp definition and other applicable statutes.
For CBD, food, supplement, cosmetic, or drug products, FDA requirements may also become important.
The company should separately conduct a comprehensive trademark clearance search, confirm ownership, select the correct filing basis, prepare an accurate identification, and review any specimen that will be submitted.
This analysis should occur before substantial investment in packaging, signage, advertising, real estate, licensing arrangements, or a public launch.
Frequently Asked Questions About Cannabis Trademarks
Can cannabis companies obtain federal trademarks in 2026?
Yes, in some circumstances. Federal registration may be available when the company’s particular goods or services can be lawfully offered in federal commerce and the mark satisfies ordinary USPTO requirements.
Did the federal government legalize marijuana in April 2026?
No. The April 28, 2026 rule created Schedule III treatment for specified FDA-approved marijuana drug products and marijuana subject to qualifying state medical-marijuana licenses. It did not broadly legalize all marijuana.
Is all marijuana Schedule III now?
No. A separate federal proceeding continues to consider broader transfer of marijuana from Schedule I to Schedule III. As of September 1, 2026, that broader proposal has not become a final rule applicable to marijuana generally.
Can a state-licensed medical marijuana business apply for a federal trademark?
Potentially. The April 2026 framework creates a significantly more viable pathway, but the company should also determine whether applicable DEA registration and other federal requirements have been satisfied.
Can a recreational dispensary obtain a federal trademark?
Federal registration for services directly involving adult-use marijuana remains significantly more difficult because recreational marijuana is outside the limited medical-marijuana framework established by the April 2026 final rule.
Can a cannabis company trademark its name for clothing?
Potentially, if the company genuinely sells clothing under the mark and satisfies ordinary trademark requirements. A clothing registration does not automatically protect marijuana or dispensary services.
Can cannabis software be federally trademarked?
Potentially. Independently lawful software and technology services serving the cannabis industry may qualify for federal trademark registration depending on the actual services and application wording.
Can a cannabis company trademark hemp products?
Potentially. Hemp follows a separate federal analysis because qualifying hemp is excluded from the definition of marijuana. Other federal statutes may still apply depending on the product.
Can a marijuana business file an intent-to-use trademark?
Potentially, but the applicant must possess a bona fide intention to make lawful use of the mark. Filing under Section 1(b) does not eliminate federal-law restrictions.
Can a cannabis company use a state trademark instead?
Potentially. State registration may be available when the activity is lawful under the relevant state’s law. The scope and benefits of state registration differ from federal registration.
Does a DEA registration guarantee USPTO approval?
No. Even when the underlying activity is federally lawful, the USPTO can still refuse a mark for likelihood of confusion, descriptiveness, ownership, specimen, identification, or other trademark issues.
What is the biggest mistake cannabis businesses make before filing?
One recurring mistake is treating “cannabis” as one legal category. Medical marijuana, adult-use marijuana, hemp, CBD, FDA-approved drugs, software, merchandise, and other ancillary services can each require a different federal trademark analysis.
Final Thoughts: Can Cannabis Companies Obtain Federal Trademark Protection?
Yes, but the answer is now more nuanced than it was before 2026.
The April 28, 2026 federal rule created an important new pathway for FDA-approved marijuana drug products and marijuana subject to qualifying state medical-marijuana licenses.
For those businesses, federal trademark registration may now be significantly more realistic, provided the applicant also satisfies applicable DEA requirements and ordinary USPTO trademark rules.
Adult-use marijuana businesses remain in a different position. The federal government is separately considering broader marijuana rescheduling, but as of September 1, 2026 that proceeding has not produced a final rule transferring marijuana generally to Schedule III.
Hemp, CBD, ancillary technology services, merchandise, and other lawful offerings require still different analyses.
For cannabis businesses, the most effective trademark strategy is therefore product-specific and activity-specific.
Before filing, the company should determine exactly what it sells, which entity owns the trademark, which federal statutes apply, whether required licensing and registrations are in place, and whether the proposed mark conflicts with earlier trademark rights.
Federal cannabis law is evolving rapidly, but trademark applications must be based on the law and commercial activity that actually exist, not on anticipated future legalization.
Primary Authorities and Sources
The principal authorities relevant to this article include Sections 1, 2, and 45 of the Trademark Act; 15 U.S.C. §§1051, 1052, and 1127; 37 C.F.R. §2.69; TMEP §907 concerning lawful use and compliance with federal statutes; USPTO Examination Guide 1-19 concerning cannabis and cannabis-related goods following the 2018 Farm Bill; the Controlled Substances Act; the April 28, 2026 Department of Justice and DEA final rule published at 91 Fed. Reg. 22714; current DEA marijuana-rescheduling materials; and relevant TTAB decisions including In re Brown and In re PharmaCann LLC.
Author: Abraham Cohn, Founder, Cohn Legal, PLLC. Abraham Cohn is a U.S. trademark attorney who advises businesses on trademark clearance, federal trademark registration, USPTO applications, Office Actions, brand protection, and trademark disputes.